|
1
|
Novoa-Vargas A: Natural history of ovary
cancer. Ginecol Obstet Mex. 82:613–622. 2014.(In Spanish).
PubMed/NCBI
|
|
2
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Garofalo M and Croce CM: microRNAs: Master
regulators as potential therapeutics in cancer. Annu Rev Pharmacol
Toxicol. 51:25–43. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mendell JT and Olson EN: MicroRNAs in
stress signaling and human disease. Cell. 148:1172–1187. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang J, Guo H, Zhang H, Wang H, Qian G,
Fan X, Hoffman AR, Hu JF and Ge S: Putative tumor suppressor
miR-145 inhibits colon cancer cell growth by targeting oncogene
Friend leukemia virus integration 1 gene. Cancer. 117:86–95. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu Z, Xu T, Wang L, Wang X, Zhong S, Xu C
and Shen Z: MicroRNA-145 directly targets the insulin-like growth
factor receptor I in human bladder cancer cells. FEBS Lett.
588:3180–3185. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sachdeva M, Zhu S, Wu F, Wu H, Walia V,
Kumar S, Elble R, Watabe K and Mo YY: p53 represses c-Myc through
induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA.
106:3207–3212. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang J, Guo H, Qian G, Ge S, Ji H, Hu X
and Chen W: MiR-145, a new regulator of the DNA fragmentation
factor-45 (DFF45)-mediated apoptotic network. Mol Cancer.
9:2112010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sachdeva M and Mo YY: MicroRNA-145
suppresses cell invasion and metastasis by directly targeting mucin
1. Cancer Res. 70:378–387. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li
D, Lai L and Jiang BH: MiR-145 directly targets p70S6K1 in cancer
cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res.
40:761–774. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cho WC, Chow AS and Au JS: MiR-145
inhibits cell proliferation of human lung adenocarcinoma by
targeting EGFR and NUDT1. RNA Biol. 8:125–131. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chan M, Liaw CS, Ji SM, Tan HH, Wong CY,
Thike AA, Tan PH, Ho GH and Lee AS: Identification of circulating
microRNA signatures for breast cancer detection. Clin Cancer Res.
19:4477–4487. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gramantieri L, Fornari F, Ferracin M,
Veronese A, Sabbioni S, Calin GA, Grazi GL, Croce CM, Bolondi L and
Negrini M: MicroRNA-221 targets Bmf in hepatocellular carcinoma and
correlates with tumor multifocality. Clin Cancer Res. 15:5073–5081.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ichimi T, Enokida H, Okuno Y, Kunimoto R,
Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama
K, et al: Identification of novel microRNA targets based on
microRNA signatures in bladder cancer. Int J Cancer. 125:345–352.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Amaral FC, Torres N, Saggioro F, Neder L,
Machado HR, Silva WJ Jr, Moreira AC and Castro M: MicroRNAs
differentially expressed in ACTH-secreting pituitary tumors. J Clin
Endocrinol Metab. 94:320–323. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot
CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, et al: Integrated
analyses identify a master microRNA regulatory network for the
mesenchymal subtype in serous ovarian cancer. Cancer Cell.
23:186–199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chung YW, Bae HS, Song JY, Lee JK, Lee NW,
Kim T and Lee KW: Detection of microRNA as novel biomarkers of
epithelial ovarian cancer from the serum of ovarian cancer
patients. Int J Gynecol Cancer. 23:673–679. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Letelier P, García P, Leal P, Álvarez H,
Ili C, López J, Castillo J, Brebi P and Roa JC: miR-1 and miR-145
act as tumor suppressor microRNAs in gallbladder cancer. Int J Clin
Exp Pathol. 7:1849–1867. 2014.PubMed/NCBI
|
|
20
|
Wu H, Xiao Z, Wang K, Liu W and Hao Q:
MiR-145 is downregulated in human ovarian cancer and modulates cell
growth and invasion by targeting p70S6K1 and MUC1. Biochem Biophys
Res Commun. 441:693–700. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang W, Wang Q, Yu M, Wu N and Wang H:
MicroRNA-145 function as a cell growth repressor by directly
targeting c-Myc in human ovarian cancer. Technol Cancer Res Treat.
13:161–168. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Q, Sakamoto K and Wagner KU: D-type
Cyclins are important downstream effectors of cytokine signaling
that regulate the proliferation of normal and neoplastic mammary
epithelial cells. Mol Cell Endocrinol. 382:583–592. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kato JY and Sherr CJ: Inhibition of
granulocyte differentiation by G1 cyclins D2 and D3 but not D1.
Proc Natl Acad Sci USA. 90:11513–11517. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Song H, Hogdall E, Ramus SJ, Dicioccio RA,
Hogdall C, Quaye L, McGuire V, Whittemore AS, Shah M, Greenberg D,
et al: Effects of common germ-line genetic variation in cell cycle
genes on ovarian cancer survival. Clin Cancer Res. 14:1090–1095.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rady B, Chen Y, Vaca P, Wang Q, Wang Y,
Salmon P and Oberholzer J: Overexpression of E2F3 promotes
proliferation of functional human β cells without induction of
apoptosis. Cell Cycle. 12:2691–2702. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bracken AP, Ciro M, Cocito A and Helin K:
E2F target genes: Unraveling the biology. Trends Biochem Sci.
29:409–417. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Johnson DG, Schwarz JK, Cress WD and
Nevins JR: Expression of transcription factor E2F1 induces
quiescent cells to enter S phase. Nature. 365:349–352. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nevins JR: E2F: A link between the Rb
tumor suppressor protein and viral oncoproteins. Science.
258:424–429. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Blais A and Dynlacht BD: Hitting their
targets: An emerging picture of E2F and cell cycle control. Curr
Opin Genet Dev. 14:527–532. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu H, Dougherty U, Robinson V, Mustafi R,
Pekow J, Kupfer S, Li YC, Hart J, Goss K, Fichera A, et al: EGFR
signals downregulate tumor suppressors miR-143 and miR-145 in
Western diet-promoted murine colon cancer: Role of G1 regulators.
Mol Cancer Res. 9:960–975. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Le Beau MM, Lemons RS, Espinosa R III,
Larson RA, Arai N and Rowley JD: Interleukin-4 and interleukin-5
map to human chromosome 5 in a region encoding growth factors and
receptors and are deleted in myeloid leukemias with a del(5q).
Blood. 73:647–650. 1989.PubMed/NCBI
|
|
33
|
Zhu X, Li Y, Xie C, Yin X, Liu Y, Cao Y,
Fang Y, Lin X, Xu Y, Xu W, et al: miR-145 sensitizes ovarian cancer
cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer.
135:1286–1296. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gadducci A, Sergiampietri C, Lanfredini N
and Guiggi I: Micro-RNAs and ovarian cancer: The state of art and
perspectives of clinical research. Gynecol Endocrinol. 30:266–271.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shi B, Sepp-Lorenzino L, Prisco M, Linsley
P, DeAngelis T and Baserga R: Micro RNA 145 targets the insulin
receptor substrate-1 and inhibits the growth of colon cancer cells.
J Biol Chem. 282:32582–32590. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
La Rocca G, Badin M, Shi B, Xu SQ,
Deangelis T, Sepp-Lorenzinoi L and Baserga R: Mechanism of growth
inhibition by MicroRNA 145: The role of the IGF-I receptor
signaling pathway. J Cell Physiol. 220:485–491. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fuse M, Nohata N, Kojima S, Sakamoto S,
Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Naya Y, Ichikawa T
and Seki N: Restoration of miR-145 expression suppresses cell
proliferation, migration and invasion in prostate cancer by
targeting FSCN1. Int J Oncol. 38:1093–1101. 2011.PubMed/NCBI
|
|
38
|
Speranza MC, Frattini V, Pisati F, Kapetis
D, Porrati P, Eoli M, Pellegatta S and Finocchiaro G: NEDD9, a
novel target of miR-145, increases the invasiveness of
glioblastoma. Oncotarget. 3:723–734. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu CC, Tsai LL, Wang ML, Yu CH, Lo WL,
Chang YC, Chiou GY, Chou MY and Chiou SH: miR145 targets the
SOX9/ADAM17 axis to inhibit tumor-initiating cells and
IL-6-mediated paracrine effects in head and neck cancer. Cancer
Res. 73:3425–3440. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sherr CJ: G1 phase progression: Cycling on
cue. Cell. 79:551–555. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Weinberg RA: The retinoblastoma protein
and cell cycle control. Cell. 81:323–330. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Trimarchi JM and Lees JA: Sibling rivalry
in the E2F family. Nat Rev Mol Cell Biol. 3:11–20. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
He Y, Franco OE, Jiang M, Williams K, Love
HD, Coleman IM, Nelson PS and Hayward SW: Tissue-specific
consequences of cyclin D1 overexpression in prostate cancer
progression. Cancer Res. 67:8188–8197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chang L, Guo R, Yuan Z, Shi H and Zhang D:
LncRNA HOTAIR regulates CCND1 and CCND2 expression by sponging
miR-206 in ovarian cancer. Cell Physiol Biochem. 49:1289–1303.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Reimer D, Hubalek M, Riedle S, Skvortsov
S, Erdel M, Concin N, Fiegl H, Müller-Holzner E, Marth C, Illmensee
K, et al: E2F3a is critically involved in epidermal growth factor
receptor-directed proliferation in ovarian cancer. Cancer Res.
70:4613–4623. 2010. View Article : Google Scholar : PubMed/NCBI
|
